SUBSCRIBERS
Trendlines Group still a 'buy': DBS research
Published Thu, Mar 17, 2016 · 09:50 PM
'%3e%3cpath%20d='M20.7725%2026.9924C20.9555%2026.9924%2021.1297%2026.953%2021.2951%2026.8741C21.4604%2026.7953%2021.6346%2026.6694%2021.8177%2026.4965L27.8373%2020.8125C27.9848%2020.6752%2028.0865%2020.5353%2028.1425%2020.3929C28.1985%2020.2505%2028.2264%2020.1183%2028.2264%2019.9962C28.2264%2019.869%2028.1985%2019.7343%2028.1425%2019.5918C28.0865%2019.4494%2027.9848%2019.3095%2027.8373%2019.1722L21.8177%2013.5417C21.6142%2013.3484%2021.4375%2013.2098%2021.2875%2013.1259C21.1374%2013.042%2020.9708%2013%2020.7877%2013C20.5181%2013%2020.2981%2013.0916%2020.1278%2013.2747C19.9574%2013.4578%2019.8722%2013.6765%2019.8722%2013.9308V16.8147H19.6509C18.2827%2016.8147%2017.1014%2017.0258%2016.107%2017.448C15.1127%2017.8701%2014.2963%2018.4805%2013.658%2019.279C13.0197%2020.0776%2012.5466%2021.0402%2012.2389%2022.1668C11.9312%2023.2934%2011.7773%2024.5612%2011.7773%2025.9701C11.7773%2026.3006%2011.8575%2026.5537%2012.0177%2026.7291C12.1779%2026.9047%2012.3597%2026.9924%2012.5632%2026.9924C12.7259%2026.9924%2012.89%2026.9593%2013.0553%2026.8932C13.2206%2026.8271%2013.3693%2026.6719%2013.5016%2026.4278C13.9441%2025.5936%2014.4553%2024.9413%2015.0351%2024.4708C15.6149%2024.0004%2016.2838%2023.6685%2017.0417%2023.4752C17.7995%2023.2819%2018.6693%2023.1853%2019.6509%2023.1853H19.8722V26.0998C19.8722%2026.3591%2019.9574%2026.5728%2020.1278%2026.7406C20.2981%2026.9085%2020.513%2026.9924%2020.7725%2026.9924Z'%20fill='black'%20fill-opacity='0.85'/%3e%3c/g%3e%3crect%20x='0.5'%20y='0.5'%20width='39'%20height='39'%20rx='19.5'%20stroke='%23F2F2F2'/%3e%3cdefs%3e%3cclipPath%20id='clip0_715_28555'%3e%3crect%20width='16.4491'%20height='14'%20fill='white'%20transform='translate(11.7773%2013)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e){kind=small}
Singapore
DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.
It is "not a material loss", DBS analyst Sachin Mittal said in a note on Thursday. "Given that medtech companies comprise an estimated 70-8…
'/%3e%3cpath%20d='M35.1847%2014.0422L9.37867%2024.1703C8.88772%2024.363%208.86989%2025.051%209.35015%2025.2688L15.0551%2027.8567C15.2097%2027.9269%2015.327%2028.0594%2015.3778%2028.2212L17.8255%2036.0078C17.9491%2036.4009%2018.4247%2036.5534%2018.7539%2036.3054L23.0143%2033.0968C23.2178%2032.9435%2023.4961%2032.9364%2023.7072%2033.0787L30.8526%2037.8975C31.2091%2038.1378%2031.6951%2037.9339%2031.7732%2037.5114L35.9896%2014.7059C36.0747%2014.2456%2035.6206%2013.8712%2035.1847%2014.0422Z'%20fill='%23FDFEFF'/%3e%3cpath%20d='M15.3125%2027.9998L30.4162%2018.627L19.3691%2029.3628L19.548%2033.3966L18.9531%2036.1248C18.3783%2036.7236%2017.9297%2036.2772%2017.8477%2036.0662L15.3681%2028.178L15.2734%2028.0233L15.3125%2027.9998Z'%20fill='%23C8DAEA'/%3e%3cpath%20d='M18.3594%2036.4259L19.3511%2029.3447L23.519%2032.9856C23.303%2032.9612%2023.1588%2032.9863%2023.0268%2033.0859L19.0712%2036.0718C18.6289%2036.4572%2018.4297%2036.4455%2018.3594%2036.4259Z'%20fill='%23A9C9DD'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear'%20x1='33'%20y1='7.5'%20x2='19'%20y2='36.5'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231E96C8'/%3e%3cstop%20offset='1'%20stop-color='%2337AEE2'%20stop-opacity='0'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
LVMH’s first quarter sales growth slips to 3% on luxury slowdown
AMD introduces AI chips for business laptops and desktops
Microsoft-backed Rubrik targets up to US$5.4 billion valuation in US IPO
BYD unveils two models in latest luxury sport utility push
US: Dow, S&P open higher as upbeat earnings obscure Mid-east jitters
J&J profit beats Wall Street estimates
